Raymond James Reinstates Outperform on Biomarin Pharmaceutical, Announces $79 Price Target
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Danielle Brill has reinstated an Outperform rating on Biomarin Pharmaceutical (NASDAQ:BMRN) with a price target of $79.
October 10, 2024 | 1:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Raymond James has reinstated an Outperform rating on Biomarin Pharmaceutical with a price target of $79, indicating a positive outlook.
The reinstatement of an Outperform rating by a reputable analyst and a specific price target of $79 suggests a positive short-term impact on Biomarin's stock price. This indicates confidence in the company's performance and potential for growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100